US Stock Market Move | Mipletamig therapy achieves an 85% remission rate in leukemia patients. Aptevo Therapeutics (APVO.US) surges over 130%.

On Wednesday, Aptevo Therapeutics (APVO.US) surged over 130%, reaching $6.52. On the news front, the company announced that its mipletamig combination therapy achieved an 85% response rate in frontline acute myeloid leukemia patients. According to the 1b/2 phase Rainer trial results reported by Aptevo, mipletamig's treatment approach showed strong efficacy and safety in patients who are not suitable for chemotherapy. The third cohort of the trial is close to full enrollment at the highest dose level being tested, and the company's optimism is giving it confidence in the potential of mipletamig.